News Release

Circular RNAs open new frontiers in hepatitis B virus-induced liver cancer

Peer-Reviewed Publication

Compuscript Ltd

fig 1

image: 

 

 

Image Caption: Part 1: The process of HBV infection and replication in cells: (A) HBV enters the liver cell via fusion and endocytosis.

Image link: https://ars.els-cdn.com/content/image/1-s2.0-S2352304225000947-gr1_lrg.jpg  

 

 

 


g

view more 

Credit: Genes & Diseases

Hepatitis B virus-induced hepatocellular carcinoma (HCC) remains a major global health burden, and new therapeutic and diagnostic approaches are urgently needed. Emerging research highlights the crucial role of circular RNAs (circRNAs) in disease progression, offering promising avenues for early detection and innovative treatments. These non-coding RNA molecules, known for their stability and regulatory functions, are proving to be pivotal in tumor biology and immune response modulation.

 

Unlike linear RNAs, circRNAs have a closed-loop structure that makes them resistant to degradation, allowing them to serve as long-lasting regulators of gene expression. They influence multiple cancer-related processes, including tumor proliferation, metastasis, immune evasion, and drug resistance. Specific circRNAs such as circRNA-100338, circRNA-101764, and circBACH1 have been identified as key players in HCC progression, affecting crucial signaling pathways like PI3K/Akt, Wnt/β-catenin, and NF-κB. By acting as molecular sponges for microRNAs (miRNAs), these circRNAs help modulate cancer-promoting genes, making them attractive targets for therapeutic intervention.

 

The potential of circRNAs extends beyond treatment to early diagnosis and prognostic evaluation. Blood-based biomarkers, including circRNA panels, have demonstrated high specificity and sensitivity in distinguishing HCC from chronic hepatitis B and cirrhosis, outperforming traditional markers like alpha-fetoprotein (AFP). With liquid biopsy techniques gaining traction, circRNAs could revolutionize non-invasive cancer detection, enabling early intervention and improved patient outcomes.

 

Targeting circRNAs for therapy is an exciting frontier in RNA-based medicine. Cutting-edge approaches, including RNA interference (RNAi), CRISPR-based gene editing, and nanoparticle delivery systems, are being explored to selectively suppress tumor-promoting circRNAs or restore tumor-suppressive ones. Additionally, circRNA-based vaccines are under development, leveraging their ability to encode therapeutic proteins while avoiding rapid degradation.

 

Advancements in high-throughput sequencing and bioinformatics are accelerating circRNA research, providing deeper insights into their functional mechanisms in liver cancer. However, challenges remain in translating these findings into clinical applications, including the need for precise delivery systems, validation in large-scale studies, and better understanding of circRNA interactions with host immune pathways.

 

# # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus CiteScore: 8.4

Impact Factor: 6.9

 

# # # # # #

 

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/

Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/

All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases ).

Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).

Print ISSN: 2352-4820

eISSN: 2352-3042

CN: 50-1221/R

Contact Us: editor@genesndiseases.com

X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases )

 

# # # # # #

Reference

Wenjun Quan, Kizito Eneye Bello, Rafidah Hanim Shueb, Nazri Mustaffa, Circular RNAs in hepatitis B virus-induced hepatocellular carcinoma: A comprehensive review and recent advances, Genes & Diseases, Volume 12, Issue 5, 2025, 101605, https://doi.org/10.1016/j.gendis.2025.101605

 

Funding Information:

Universiti Sains Malaysia 1001.PPSP.8012343

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.